BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

789 related articles for article (PubMed ID: 28579757)

  • 1. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.
    Raimondo MG; Biggioggero M; Crotti C; Becciolini A; Favalli EG
    Drug Des Devel Ther; 2017; 11():1593-1603. PubMed ID: 28579757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sarilumab: Review of a Second IL-6 Receptor Antagonist Indicated for the Treatment of Rheumatoid Arthritis.
    Boyce EG; Rogan EL; Vyas D; Prasad N; Mai Y
    Ann Pharmacother; 2018 Aug; 52(8):780-791. PubMed ID: 29482351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis.
    June RR; Olsen NJ
    Expert Opin Biol Ther; 2016 Oct; 16(10):1303-9. PubMed ID: 27464017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the efficacy and tolerability of tocilizumab, sarilumab, and sirukumab in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
    Bae SC; Lee YH
    Clin Rheumatol; 2018 Jun; 37(6):1471-1479. PubMed ID: 29404725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of sarilumab for the treatment of rheumatoid arthritis.
    Lee EB
    Immunotherapy; 2018 Jan; 10(1):57-65. PubMed ID: 29043871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.
    Huizinga TW; Fleischmann RM; Jasson M; Radin AR; van Adelsberg J; Fiore S; Huang X; Yancopoulos GD; Stahl N; Genovese MC
    Ann Rheum Dis; 2014 Sep; 73(9):1626-34. PubMed ID: 24297381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis.
    Lamb YN; Deeks ED
    Drugs; 2018 Jun; 78(9):929-940. PubMed ID: 29931592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
    Strand V; Gossec L; Proudfoot CWJ; Chen CI; Reaney M; Guillonneau S; Kimura T; van Adelsberg J; Lin Y; Mangan EK; van Hoogstraten H; Burmester GR
    Arthritis Res Ther; 2018 Jun; 20(1):129. PubMed ID: 29921318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of High Serum Interleukin-6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis.
    Boyapati A; Schwartzman S; Msihid J; Choy E; Genovese MC; Burmester GR; Lam G; Kimura T; Sadeh J; Weinreich DM; Yancopoulos GD; Graham NMH
    Arthritis Rheumatol; 2020 Sep; 72(9):1456-1466. PubMed ID: 32343882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection.
    Biggioggero M; Crotti C; Becciolini A; Favalli EG
    Drug Des Devel Ther; 2019; 13():57-70. PubMed ID: 30587928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What's the Difference?
    Avci AB; Feist E; Burmester GR
    BioDrugs; 2018 Dec; 32(6):531-546. PubMed ID: 30488231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan.
    Tanaka Y; Wada K; Takahashi Y; Hagino O; van Hoogstraten H; Graham NMH; Kameda H
    Arthritis Res Ther; 2019 Mar; 21(1):79. PubMed ID: 30894208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the efficacy and safety of tocilizumab, sarilumab, and sirukumab in comparison with adalimumab as monotherapy in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
    Sung YK; Lee YH
    Int J Clin Pharmacol Ther; 2021 Sep; 59(9):618-626. PubMed ID: 34281633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future.
    Kim GW; Lee NR; Pi RH; Lim YS; Lee YM; Lee JM; Jeong HS; Chung SH
    Arch Pharm Res; 2015; 38(5):575-84. PubMed ID: 25648633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the efficacy and safety of tocilizumab, sarilumab, and olokizumab in patients with active rheumatoid arthritis: a network meta-analysis of randomized controlled trials.
    Ho Lee Y; Gyu Song G
    Z Rheumatol; 2024 Feb; 83(Suppl 1):97-106. PubMed ID: 36607422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease-Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis.
    Lee EB; Daskalakis N; Xu C; Paccaly A; Miller B; Fleischmann R; Bodrug I; Kivitz A
    Clin Pharmacokinet; 2017 Jun; 56(6):607-615. PubMed ID: 27722854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tocilizumab in rheumatoid arthritis].
    Rueda Gotor J; Blanco Alonso R
    Reumatol Clin; 2011 Mar; 6S3():S29-32. PubMed ID: 21794769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial.
    Strand V; Kosinski M; Chen CI; Joseph G; Rendas-Baum R; Graham NM; van Hoogstraten H; Bayliss M; Fan C; Huizinga T; Genovese MC
    Arthritis Res Ther; 2016 Sep; 18(1):198. PubMed ID: 27600829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rheumatoid arthritis: new monoclonal antibodies.
    Serio I; Tovoli F
    Drugs Today (Barc); 2018 Mar; 54(3):219-230. PubMed ID: 29771256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment.
    Genovese MC; van der Heijde D; Lin Y; St John G; Wang S; van Hoogstraten H; Gómez-Reino JJ; Kivitz A; Maldonado-Cocco JA; Seriolo B; Stanislav M; Burmester GR
    RMD Open; 2019; 5(2):e000887. PubMed ID: 31452928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.